Momelotinib vs Ruxolitinib for Patients With Myelofibrosis

Share this content:
Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.
Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.
The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor's conference coverage.

Momelotinib, an oral Janus kinase (JAK) inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis not previously treated with a JAK inhibitor, according to a presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1

Presenter Ruben A. Mesa, MD, from the Mayo Clinic in Scottsdale, Arizona, indicated that more than 50% of patients show mutations in JAK2 V617F.

For the phase 3 Simplify 1 study (ClinicalTrials.gov Identifier: NCT01969838), patients were randomly assigned to receive momelotinib (215 patients) or ruxolitinib (217 patients) for 24 weeks.

The primary endpoint was splenic response rate (SRR; at least 35% reduction in volume from baseline) at 24 weeks.

At 24 weeks, 81% and 93% of patients in the momelotinib and ruxolitinib arms, respectively, completed 24-week therapy.

After 24 weeks, momelotinib was deemed non-inferior to ruxolitinib: SRRs were 26.5% for momelotinib and 29.0% for ruxolitinib (P = .011).

For patient-reported Total Symptom Score (TSS), response rate for momelotinib was inferior to ruxolitinib: 28.4% vs 42.2% for ruxolitinib (P = .98).

The most common grade 3 or worse events among patients on momelotinib were thrombocytopenia (7%) and anemia (6%). Grade 3 or worse adverse events among patients on ruxolitinib included anemia (23%), thrombocytopenia (5%), and neutropenia (5%).

Adverse events leading to treatment discontinuation occurred in 13% of patients on momelotinib and 6% of patients on ruxolitinib.

“Momelotinib was non-inferior to ruxolitinib for the primary endpoint of splenic response rate, but failed to meet the non-inferiority criterion for the key secondary endpoint of symptom response,” Dr Mesa said.

RELATED: Momelotinib for Previously Treated Patients With Myelofibrosis

Read more of Cancer Therapy Advisor's coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.

Reference

  1. Mesa RA, Kiladjian JJ, Catalano JV, et al. Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naïve patients with myelofibrosis (MF). J Clin Oncol. 2017;35(suppl; abstr 7000).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters